June Lee, M.D.

Dr. June Lee was most recently Founder and CEO of Esker Therapeutics. Previously, she served as Chief Development Officer and Chief Operating Officer of MyoKardia, Inc., where she built and led a world-class development organization culminating in the company’s $13.1 billion acquisition by Bristol Myers Squibb. Prior to MyoKardia, Dr. Lee was Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator at UCSF for early-stage technologies in therapeutics, devices, diagnostics, and digital health. Previously, she was therapeutic area head in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech.

She currently serves on Johns Hopkins University Center for Therapeutic Translation’s Advisory Board, is a member of the Board of Directors for Eledon Pharmaceuticals Inc., GenEdit and Abivax, and is a member of the Scientific Advisory Board for Foresite Labs.

Dr. Lee completed a Bachelor of Science in chemistry at Johns Hopkins University, an M.D. at the School of Medicine at the University of California, Davis, and her clinical training in internal medicine and pulmonary & critical care at UCLA and UCSF.